Head-to-head evidence
Lenalidomide vs Pomalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Lenalidomide
Marketed by Celgene Corporation and partners
NCT00056160 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 353 patients with previously treated multiple myeloma and used a hard clinical primary endpoint, time to tumor progression. The primary comparison was met: median TTP was 60.1 weeks (95% CI 41.1–80.0) with lenalidomide plus dexamethasone versus 20.1 weeks (95% CI 16.1–21.1) with placebo plus dexamethasone, a large, clearly favorable separation. The trial's strong design and positive primary result make this high-quality evidence for lenalidomide.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
Pomalidomide
Marketed by Bristol-Myers Squibb
NCT01311687 · Phase 3 · completed
This was a large, randomized 2:1 active-controlled trial involving 302 participants assigned to pomalidomide plus low-dose dexamethasone and 153 assigned to high-dose dexamethasone, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, progression-free survival, was met: median PFS was 15.7 versus 8.0 weeks, with HR 0.45 (95% CI 0.35–0.59; p<0.001), supporting a moderate evidence grade.
Next expected readout: October 2026 · NCT05581875 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenalidomide's landscape · Pomalidomide's landscape